Last reviewed · How we verify
NCT04966923: BREAST-TP53
Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53
trial testing No intervention in this study in Breast Cancer in 135 participants. Completed in 22 February 2022.
7 August 2021
Quick facts
| Lead sponsor | Instituto do Cancer do Estado de São Paulo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 135 |
| Start date | 2 December 2018 |
| Primary completion | 7 August 2021 |
| Estimated completion | 22 February 2022 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- No intervention in this study
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- TP53 R337H — all drugs for TP53 R337H →
- Li-Fraumeni Syndrome — all drugs for Li-Fraumeni Syndrome →
- Prognosis Breast Cancer — all drugs for Prognosis Breast Cancer →
Sponsor
Instituto do Cancer do Estado de São Paulo — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or TP53 R337H. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective and retrospective cohort study of patients with a documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and breast cancer diagnosis by histological confirmation, between 1999 and 2022. All patients were followed by the Hereditary Group of a single cancer center (Instituto do Cancer do Estado de Sao Paulo). Patients were included if they had a histopathological diagnosis of localized invasive carcinoma or in situ carcinoma of the breast and with localized disease. Patients met Revised Chompret criteria, Li Fraumeni like syndrome,family member of carrier TP53 or hereditary breast and ovarian syndrome for germline test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04966923
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention in this study
Trials testing the same drug.
- NCT06511492 — Longitudinal Surveillance of Rectal Colonization and Transmission by Resistant Bacteria in Acutely Decompensated Cirrhos · not yet recruiting
- NCT06377774 — To Optimize Therapeutic Procedures of DPMAS in ACLF Patients: a Prospective, Sigle Arm and Multicenter Study · not yet recruiting
- NCT03154203 — Non-Invasive Aortic Ambulatory Blood Pressure Monitoring for The Detection of Target Organ Damage in The Chinese Populat · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Instituto do Cancer do Estado de São Paulo trials
Trials by the same sponsor.
- NCT06887621 — Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk f · Phase 2 · recruiting
- NCT07066046 — Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions · NA · recruiting
- NCT06282354 — Telemedicine for Postoperative Follow-up After Oncological Surgeries · unknown
- NCT05622136 — Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma · Phase 2 · active not recruiting
- NCT05996367 — Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04966923 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto do Cancer do Estado de São Paulo
- Last refreshed: 9 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04966923.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing